Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2014, vol. 20, issue 6
Subject Collection: Medicine
Pages: 539-541
DOI: 10.5272/jimab.2014206.539
Published online: 04 November 2014

J of IMAB 2014 Oct-Dec;20(6):539-541
Mirena Valkova1 Corresponding Autor, Boyko Stamenov1, Dora Peychinska1, Ivanka Veleva2, Pepa Dimitrova2, Pavlina Radeva2.
1) Clinic of Neurology, UMHAT "Dr G. Stranski", Pleven, Bulgaria,
2) Psychiatric Department, Medical University – Pleven, Bulgaria.

Introduction: Metoclopramide is a dopamine receptor agonist and well known antiemetic and gastrokynetic agent. Its usage has been restricted by European Medicines Agency (EMA), because of acute and chronic neurological adverse events. Extrapyramidal syndromes, including parkinsonism, tardive dyskinesia, akathisia and acute dystonias, are the most reported and most often drug side effects.
 Contingent and methods: We present a case of 23 years old woman with a 3-year history of Metoclopramide-induced recurrent oculogyric crises.
Results: The patient suffered from examinophobia, with minimal benzodiazepine symptoms relief. She willfully took small dosages of oral Metoclopramide for nausea relief before her examinations, which lead to recurrent oculogyric crises, short after the drug intake. After a detailed explanation of drug side effects and medicine discontinuation, they disappeared. She had no significant medical and family history of neurological and psychiatric conditions. Laboratory data were normal.
Conclusions: Metoclopramide could induce acute or chronic neurological conditions and its usage should be restricted in general population to some specific conditions. Some of its adverse reactions are often misdiagnosed and improperly treated. Critical drug anamnesis with a focus on Metoclopramide usage in some cases could enhance diagnosis.

Key words: Metoclopramide side effects, dopamine antagonist, oculogyric crises,

- Download FULL TEXT /PDF 531 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Valkova M, Stamenov B, Peychinska D, Veleva I, Dimitrova P, Radeva P. Metoclopramide - induced extrapyramidal signs and symptoms - brief review of literature and case report. J of IMAB. 2014 Oct-Dec;20(6):539-541.

Correspondence to: Dr. Mirena Valkova, Clinic of Neurology, UMHAT "Dr G. Stranski", 8A, Georgi Kochev str., Pleven, Bulgaria; E-mail:

1. Wallenborn J, Gelbrich G, Bulst D, Behrends K, Wallenborn H, Rohrbach A, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone:randomised double blind multicentre trial. BMJ. 2006 Aug 12;333(7563):324. [PubMed] [CrossRef]
2. Sayana A, Barshiliya Y. Comparative Study of Metoclopramide, Ondansetron, and Granisetron in Prophylaxis of Postoperative Nausea and Vomiting in Patient Undergoing Laparoscopic Cholecystectomy Under General Anaesthesia. Asian Journal of Pharmacy & Life Science. 2012 Jan-Mar;2(1):87-93.
3. Schriever J, Bühlen M, Broich K. [Current state of knowledge and developments in the prophylaxis and acute treatment of migraine.] [in German] Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz. 2014 Aug;57(8):974-82. [PubMed] [CrossRef]
4. Madjunkova S, Maltepe C, Farine D, Koren G. Patterns of antiemetic use among american women with nausea and vomiting of pregnancy. Obstet Gynecol. 2014 May;123 Suppl 1:155S. [PubMed] [CrossRef]
5. Tonini M, Cardura SM, Messoni E, Rizzi CA. Therapeutic Potential of Drugs with Mixed 5HT4 receptor Agonist/5HT3 receptor Antagonist Action in Control of Emesis. Pharmacological Research. 1995 May;31(5):257-260. [PubMed] [CrossRef]
6. Offermanns S, Rosenthal W. (Eds.) Encyclopedia of Molecular Pharmacology. Springer Science & Business Media, 2nd ed. 2008, pp. 461.
7. Smith SH, Cox LR, Smith BR. Dopamine receptor antagonists. Annals of palliative medicine. 2012 Jul ;1(2).
8. European medical agency.  European Medicines Agency recommends changes to the use of metoclopramide. 20 December 2013. EMA/13239/2014 Corr. 1 [PDF]
9. Jo YY, Kim YB, Yang MR, Chang YJ. Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit –A case report. Korean J Anesthesiol. 2012 Sep;63(3):274-6. [PubMed] [CrossRef]
10. Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs. 2008 Oct;23(5):292-9. [PubMed] [CrossRef]
11. de Ronde MW, Kingma HJ, Munts AG. [Severe parkinsonism due to metoclopramide: the importance of early recognition.] [Article in Dutch] Ned Tijdschr Geneeskd. 2013; 157(26):A6037. [PubMed]
12. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010 Jan;31(1):11-9. [PubMed] [CrossRef]
13. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive Dyskinesia and Metoclopramide Use: Effects of Cisapride Market Withdrawal. J Am Pharm Assoc (2003). 2004 Nov-Dec;44(6):661-665. [Pubmed]
14. Meyer TA, Belson TE, McAllister R. Tardive Dyskinesia: A Distressing Drug-Induced Movement Disorder. US Pharm. 2014 Jan;39(1):HS13-HS16.
15. Arumugam J, Vijayalakshmi AM. Metoclopramide - induced oculogyric crises presenting as encephalitis in a young girl. Indian J Pharmacol. 2012 Mar;44(2): 266–267. [PubMed] [CrossRef]
16. Walker M, Samii A. Chronic severe dystonia after single exposure to antiemetics. Am J Emerg Med. 2006 Jan;24(1):125-7. [PubMed] [CrossRef]
17. Van Cool AR, Doorduijn JK, Seynaeve C. Severe akathisia as a side effect of metoclopramide. Pharm World Sci. 2010 Dec;32(6):704-6. [PubMed] [CrossRef]
18. Chauhan G, Nayar P, Kashyap S. Metoclopramide-induced akathisia. J Anaesthesiol Clin Pharmacol. 2012 Oct;28(4):548–549. [PubMed] [CrossRef] .

Received: 28 August 2014
Published online: 04 November 2014

back to Online Journal